 |
|
 |
|
| MarketVIEW: Novel coronavirus [COVID-19] vaccines |
|
|
|
2022
INTERACTIVE MODEL (.xls) is updated per order#
The novel coronavirus, SARS-CoV-2 emerged from Wuhan City, Hubei Province of China in late December 2019, causing a cluster of atypical pneumonia cases among stallholders at a seafood wholesale market.
The resulting respiratory disease, later referred to as COVID-2019, was designated by the World Health Organisation (WHO) a
Public Health Emergency of International Concern (PHEIC) on the 30th January 2020 and later a global pandemic by March 11th, 2020.
COVID-19 has affected ~190 countries/territories with greater than 530 million confirmed cases and close to 6.2 million deaths (as of June 1st 2022), mainly in the elderly and those with chronic underlying conditions.
It is predicted that a large proportion of the global population will be infected with SARS-CoV-2 causing further excess morbidity, mortality and substantial economic loss. SARS-CoV-2 is related to other coronaviruses such as MERS-CoV (2012), SARS-CoV-1 (2003)
and the endemic human betacoronaviruses OC43 and HKU1 which cause the common cold. New variants such as Delta and Omicron continue to pose a threat to unvaccinated populations.
Numerous efforts have been underway to develop new prophylatic vaccines and antiviral therapeutics to address the emergence of SARS-CoV-2.
Currently, 4 Western vaccines (of 35 in use) have gained Emergency Use Approval (EUA)/FDA approval and include
Moderna Therapeutics (mRNA-1273, SPIKEVAX), Pfizer/BioNTech (BNT162b2, CORMINATY),
Janssen (JNJ-78436735, JCOVDEN) and Oxford/AstraZeneca (AZD1222, ChAdOx1-nCOV-19, Vaxzevria). CORMINATY and SPIKEVAX have gained US FDA approval and now recently,
can be used as booster shots for certain vulnerable groups. Newer Variant specific boosters and multivalent strategies (mRNA-1273.351 and mRNA.211) are now undergoing development
for the post-pandemic seasonal phase. Rival recombinant protein products e.g. GSK/Sanofi's Vidprevtyn (GSK4353001A), Novavax's (NVX-CoV2373, Nuvaxovid), GSK/Medicago's Covifenz, GSK/SK Biosciences, SKYCovione (GBP510) + other inactivated vaccines e.g., Valneva have gained use in the EU/or are undergoing submission.
Antiviral treatments such as Molnupiravir (Merck & Co) and Paxlovid (Pfizer) are now in use.
This MarketVIEW product is a comprehensive commercial evaluation containing an Executive Presentation and INTERACTIVE MS Excel Workbook(s) (.xls)
examining the potential (value/volume) of a prophylatic COVID-19 vaccine to 2045.
The model has three detailed and fully adjustable deployment scenarios which include the major Western economies, emerging economies of SE Asia, LATAM and the Far East*.
'At risk' populations or identified target segments (based on latest understanding) are included.
A review of competitor R&D activity is also provided along with a discussion of new product strategy, potential in the post-pandemic seasonal scenario
along with pricing considerations.
Adjustable features of the MS-Excel model are:
» Launch date
» Target group sequence
» % vaccine coverage per target group
» % at risk/% private sector
» Seasonal price versus pandemic price
» Yearly or bi-yearly schedule [Forthcoming Versions]
» Number of boosters/per schedule
*63 countries, 15 are rolled up, other scenarios are global - all countries
#subject to agreed specification and timeframe
>>Try a sample
by Microsoft PowerBI
THIS PRODUCT IS A SUMMARY PRESENTATION (.pdf form) + FORECAST MODEL(s) (.xls)
To order please contact your region account manager, buy "on-line" or order direct at: orders@vaczine-analytics.com
*This is a licensed product. Prices quotes are for 1 region license only. Regions are North America, or EU or ROW.
For UK orders VAT will be added at 20%. On-line prices may include discounts and are converted from list price in US dollars (subject to currency fluctuations).
Please review the TERMS and CONDITIONS of purchase.
Picture Credit: CDC (Unsplash)
|
|
|
|
|
|
